title: Percutaneous coronary interventions and antiplatelet therapy in renal transplant recipients.
abstract: Cardiovascular disease is the leading cause of mortality and morbidity following renal transplantation (RT), accounting for 40-50% of all deaths. After renal transplantation, an adverse cardiovascular event occurs in nearly 40% of patients; given the dialysis vintage and the average wait time, the likelihood of receiving coronary revascularization is very high. There is a significant gap in the literature in terms of the outcomes of prophylactic coronary revascularization in renal transplantation candidates. Current guidelines on myocardial revascularization stipulate that renal transplant patients with significant coronary artery disease (CAD) should not be excluded from the potential benefit of revascularization. Compared with percutaneous coronary intervention (PCI), however, coronary artery bypass grafting is associated with higher early and 30-day mortality. About one-third of renal transplant patients with CAD have to be treated invasively and so PCI is currently the most popular mode of revascularization in these fragile and compromised patients. A newer generation drug-eluting stent (DES) should be preferred over a bare metal stent (BMS) because of its lower risk of restenosis and improved safety concerns (stent thrombosis) compared with first generation DES and BMS. Among DES, despite no significant differences being reported in terms of efficacy, the newer everolimus and zotarolimus eluting stents should be preferred given the possibility of discontinuing, if necessary, dual antiplatelet therapy before 12 months. Since there is a lack of randomized controlled trials, the current guidelines are inadequate to provide a specifically tailored antiplatelet therapeutic approach for renal transplant patients. At present, clopidogrel is the most used agent, confirming its central role in the therapeutic management of renal transplant patients undergoing PCI. While progress in malignancy-related mortality seems a more distant target, a slow but steady reduction in cardiovascular deaths, improving pharmacological and interventional therapy, is nowadays an achievable medium-term target in renal transplant patients.
authors.affiliation: Cath-Lab/Department of Cardiology-Policlinico Casilino, Via Casilina, 1049, Rome 00199, Italy f.summaria@gmail.com.
authors.forename: Francesco
authors.initials: F
authors.lastname: Summaria
authors.affiliation: Cath-Lab/Department of Cardiology-Policlinico Casilino, Rome, Italy.
authors.forename: Maria Benedetta
authors.initials: MB
authors.lastname: Giannico
authors.affiliation: Cath-Lab/Department of Cardiology-Policlinico Casilino, Rome, Italy.
authors.forename: Giovanni Paolo
authors.initials: GP
authors.lastname: Talarico
authors.affiliation: Cath-Lab/Department of Cardiology-Policlinico Casilino, Rome, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Patrizi
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000628:therapy; D001026:Coronary Artery Bypass / Q000379:methods / Q000401:mortality; D003324:Coronary Artery Disease / Q000209:etiology / Q000628:therapy*; D054855:Drug-Eluting Stents; D006801:Humans; D016030:Kidney Transplantation / Q000379:methods*; D062645:Percutaneous Coronary Intervention / Q000379:methods* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D017410:Practice Guidelines as Topic
chemical_list: D010975:Platelet Aggregation Inhibitors
keywords: antiplatelet therapy; clopidogrel; drug covered stent; drug eluting stent; percutaneous coronary interventions; prasugrel; renal transplant recipient; ticagrelor